Castle Biosciences shared that its sales hit $102.9 million last quarter, up 24% from last year.

Nov 5, 2026, 5:28 PM ETResultsRead the original at Benzinga

Good for CSTL

Castle's revenue grew 24%, TissueCypher test reports grew 47%, and its 2026 revenue forecast rose to $385 million–$395 million. The $4.1 million net loss is a concern, but $12.7 million in adjusted EBITDA and $19.7 million in cash from operations support a positive read.

CSTL · Castle Biosciences

AI read · Good for CSTL

The AI's read

More TissueCypher tests drove sales growth, and management expects that growth to continue. The company also brought in $19.7 million from operations and held $278 million in cash and investments. Its $4.1 million net loss is a concern, but the sales growth and raised forecast support a positive read.

Get alerts for CSTL

Follow Castle Biosciences (CSTL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CSTL

Free on the App Store and Google Play, or on the web.